Real-World Effectiveness and Safety of Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Advanced Breast Cancer: A Multicenter Portuguese Study

Objective: The HER2CLIMB trial demonstrated the benefit of tucatinib, trastuzumab and capecitabine (TTC) in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC). However, it predated the clinical use of trastuzumab deruxtecan (T-DXd), leaving limited evidence for TTC...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন

প্রধান লেখক:	Rita Quaresma Ferreira, Carolina Brandão Monteiro, Ana Catarina Dias, Francisca Abreu, Bogdana Darmits, Maria João Oura, Inês Ângelo, Joana Cabral, Alice Figueiredo, Ricardo Ferreira, Diogo Alpuim Costa, Maria Teresa Marques, Tiago Pina-Cabral, Filipe Araújo, Sandra Bento, Catarina Lopes Fernandes, Mariana Santiago, Bruno Silva, Maria Alexandra Montenegro, Diana Cardoso Simão, Leonor Fernandes, Sónia Duarte Oliveira
বিন্যাস:	Artigo
ভাষা:	Inglês
প্রকাশিত:	Galenos Publishing House 2026-07-01
মালা:	European Journal of Breast Health
বিষয়গুলি:	breast cancer her2 protein tucatinib real-world data survival analysis
অনলাইন ব্যবহার করুন:	https://www.eurjbreasthealth.com/articles/real-world-effectiveness-and-safety-of-tucatinib-trastuzumab-and-capecitabine-in-her2-positive-advanced-breast-cancer-a-multicenter-portuguese-study/doi/ejbh.galenos.2026.2026-2-3
ট্যাগগুলো:	ট্যাগ যুক্ত করুন কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!